Traws Pharma (TRAW)
NASDAQ:TRAW
Want to see TRAW full AI Analyst Report?
Total Valuation
Traws Pharma has a market cap or net worth of $13.20M. The enterprise value is $6.88M.
Market Cap$13.20M
Enterprise Value$6.88M
Share Statistics
Traws Pharma has 10,157,257 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,157,257
Owned by Insiders18.73%
Owned by Institutions28.86%
Financial Efficiency
Traws Pharma’s return on equity (ROE) is -14.58 and return on invested capital (ROIC) is 3379.02%.
Return on Equity (ROE)-14.58
Return on Assets (ROA)0.86
Return on Invested Capital (ROIC)3379.02%
Return on Capital Employed (ROCE)33.79
Revenue Per Employee465.00K
Profits Per Employee1.53M
Employee Count6
Asset Turnover0.26
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Traws Pharma is 1.0. Traws Pharma’s PEG ratio is -0.00991.
PE Ratio1.0
PS Ratio3.33
PB Ratio-14.78
Price to Fair Value-14.78
Price to FCF-0.45
Price to Operating Cash Flow-0.59
PEG Ratio-0.00991
Income Statement
In the last 12 months, Traws Pharma had revenue of 2.79M and earned 9.17M in profits. Earnings per share was 0.83.
Revenue2.79M
Gross Profit2.73M
Operating Income-17.88M
Pretax Income9.17M
Net Income9.17M
EBITDA-17.81M
Earnings Per Share (EPS)0.83
Cash Flow
In the last 12 months, operating cash flow was -18.18M and capital expenditures -2.58M, giving a free cash flow of -20.77M billion.
Operating Cash Flow-18.18M
Free Cash Flow-20.77M
Free Cash Flow per Share-2.04
Dividends & Yields
Traws Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.04
52-Week Price Change-10.34%
50-Day Moving Average1.76
200-Day Moving Average1.89
Relative Strength Index (RSI)33.17
Average Volume (3m)206.36K
Important Dates
Traws Pharma upcoming earnings date is May 18, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Traws Pharma as a current ratio of 0.72, with Debt / Equity ratio of 0.00%
Current Ratio0.72
Quick Ratio0.72
Debt to Market Cap0.00
Net Debt to EBITDA0.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Traws Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Traws Pharma EV to EBITDA ratio is -0.31, with an EV/FCF ratio of -0.26.
EV to Sales1.96
EV to EBITDA-0.31
EV to Free Cash Flow-0.26
EV to Operating Cash Flow-0.30
Balance Sheet
Traws Pharma has $3.82M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.82M billion.
Cash & Marketable Securities$3.82M
Total Debt$0.00
Net Cash$3.82M
Net Cash Per Share$0.38
Tangible Book Value Per Share-$0.38
Margins
Gross margin is 100.00%, with operating margin of -640.68%, and net profit margin of 328.67%.
Gross Margin100.00%
Operating Margin-640.68%
Pretax Margin328.67%
Net Profit Margin328.67%
EBITDA Margin-638.49%
EBIT Margin-640.68%
Analyst Forecast
The average price target for Traws Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―